Loading...
Avadel Pharmaceuticals plc
AVDL•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$11.03
$-0.22(-1.96%)
Avadel Pharmaceuticals plc (AVDL) Financial Performance & Income Statement Overview
Review Avadel Pharmaceuticals plc’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
504.79%
↑ 504.79%
Operating Income Growth
69.24%
↑ 69.24%
Net Income Growth
69.53%
↑ 69.53%
Operating Cash Flow Growth
63.50%
↑ 63.50%
Operating Margin
-9.96%
↓ 9.96%
Gross Margin
90.06%
↑ 90.06%
Net Profit Margin
-13.58%
↓ 13.58%
ROE
-36.07%
↓ 36.07%
ROIC
-16.55%
↓ 16.55%
Avadel Pharmaceuticals plc (AVDL) Income Statement & Financial Overview
Review Avadel Pharmaceuticals plc's (AVDL) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $50.41M | $50.02M | $41.50M | $27.18M |
| Cost of Revenue | $4.81M | $6.16M | $2.79M | $1.52M |
| Gross Profit | $45.60M | $43.87M | $38.72M | $25.66M |
| Gross Profit Ratio | $0.90 | $0.88 | $0.93 | $0.94 |
| R&D Expenses | $4.27M | $3.80M | $4.05M | $3.07M |
| SG&A Expenses | $44.62M | $40.39M | $47.41M | $48.62M |
| Operating Expenses | $48.90M | $44.20M | $51.46M | $51.69M |
| Total Costs & Expenses | $53.71M | $50.35M | $54.24M | $53.21M |
| Interest Income | $0.00 | $0.00 | $0.00 | $2.59M |
| Interest Expense | $2.70M | $2.82M | $2.72M | $2.59M |
| Depreciation & Amortization | $668000.00 | $1.03M | $437000.00 | $541000.00 |
| EBITDA | -$1.59M | $1.32M | -$11.18M | -$24.12M |
| EBITDA Ratio | -$0.03 | $0.03 | -$0.27 | -$0.89 |
| Operating Income | -$3.30M | -$327000.00 | -$12.74M | -$26.04M |
| Operating Income Ratio | -$0.07 | -$0.007 | -$0.31 | -$0.96 |
| Other Income/Expenses (Net) | -$1.67M | -$2.21M | -$1.59M | -$1.21M |
| Income Before Tax | -$4.96M | -$2.54M | -$14.33M | -$27.25M |
| Income Before Tax Ratio | -$0.10 | -$0.05 | -$0.35 | -$1.003 |
| Income Tax Expense | $80000.00 | $88000.00 | -$509000.00 | $93000.00 |
| Net Income | -$5.04M | -$2.63M | -$13.82M | -$27.34M |
| Net Income Ratio | -$0.10 | -$0.05 | -$0.33 | -$1.006 |
| EPS | -$0.05 | -$0.03 | -$0.14 | -$0.30 |
| Diluted EPS | -$0.05 | -$0.03 | -$0.14 | -$0.30 |
| Weighted Avg Shares Outstanding | $96.39M | $96.30M | $96.15M | $91.69M |
| Weighted Avg Shares Outstanding (Diluted) | $96.39M | $96.30M | $96.15M | $91.69M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan